



Insights Into Acute Myeloid Leukemia (AML) Wednesday, September 16, 2020

Presenter: Elias Jabbour, MD
Moderator: Naval Daver, MD

AGENDA

Time (CDT)	Topic
5.30 PM – 5.45 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • Round robin introductions
5.45 PM – 6.00 PM (15 min)	ARS questions
6.00 PM – 6.30 PM (30 min)	First-Line Therapy of AML <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Factors guiding first-line therapy <ul style="list-style-type: none"> ▪ Impact of age, cytogenetics, molecular markers, comorbidities, and PS, etiology (primary, therapy-related, myelodysplasia-related changes) on induction therapy selection ▪ Standard 7+3 vs liposomal daunorubicin/cytarabine vs other intensive regimens (FLAG-IDA) vs hypomethylating agents and/or low-dose cytarabine vs gemtuzumab ▪ Postinduction consolidation therapy (HiDAC, allo-SCT) – Integration of novel agents approved and under investigation (FLT3 inhibitors, BCL2 inhibitors, Hedgehog pathway inhibitors, IDH1 inhibitors) – Maintenance therapy? – Role of MRD
6.30 PM – 7.15 PM (45 min)	Moderated Discussion
7.15 PM – 7.25 PM (10 min)	Break
7.25 PM – 7.35 PM (10 min)	ARS questions
7.35 PM – 8.00 PM (25 min)	Management of Relapsed/Refractory Disease and Promising Strategies in AML <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Factors guiding second-line and subsequent therapy <ul style="list-style-type: none"> ▪ Biomarkers at relapse ▪ Patient age, timing of relapse (<12 months vs >12 months), and role of reinduction or HCT ▪ Targeted therapy for <i>FLT3</i>-positive, <i>CD33</i>-positive, and <i>IDH1</i>- or <i>IDH2</i>-positive patients • Promising agents <ul style="list-style-type: none"> – Anti-CD47 antibody

	<ul style="list-style-type: none"> - APR-246 for <i>p53</i> mutant AML - Anti-CD70 antibody • Reaction and discussion
8.00 PM – 8.25 PM (25 min)	Moderated Discussion
8.25 PM – 8.30 PM (5 min)	Key Takeaways and Meeting Evaluation